RU2015138677A - Применение ингибиторов nkg2d для лечения сердечно-сосудистых и метаболических заболеваний, таких как диабет 2 типа - Google Patents

Применение ингибиторов nkg2d для лечения сердечно-сосудистых и метаболических заболеваний, таких как диабет 2 типа Download PDF

Info

Publication number
RU2015138677A
RU2015138677A RU2015138677A RU2015138677A RU2015138677A RU 2015138677 A RU2015138677 A RU 2015138677A RU 2015138677 A RU2015138677 A RU 2015138677A RU 2015138677 A RU2015138677 A RU 2015138677A RU 2015138677 A RU2015138677 A RU 2015138677A
Authority
RU
Russia
Prior art keywords
nkg2d
agent
antibody
binding fragment
composition
Prior art date
Application number
RU2015138677A
Other languages
English (en)
Russian (ru)
Inventor
На СЮН
Минцань СЯ
Дэвид Х. РОЛЕТ
Якоб Стен ПЕТЕРСЕН
Тоура Бринья БЕДВАРСДОУТТИР
Original Assignee
Дзе Пенн Стейт Рисерч Фаундейшн
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Пенн Стейт Рисерч Фаундейшн, Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа filed Critical Дзе Пенн Стейт Рисерч Фаундейшн
Publication of RU2015138677A publication Critical patent/RU2015138677A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
RU2015138677A 2009-08-17 2010-08-16 Применение ингибиторов nkg2d для лечения сердечно-сосудистых и метаболических заболеваний, таких как диабет 2 типа RU2015138677A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23442509P 2009-08-17 2009-08-17
US61/234,425 2009-08-17
US30411310P 2010-02-12 2010-02-12
US61/304,113 2010-02-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2012105528/15A Division RU2566264C2 (ru) 2009-08-17 2010-08-16 Применение ингибиторов nkg2d для лечения сердечно-сосудистых и метаболических заболеваний, таких как диабет 2 типа

Publications (1)

Publication Number Publication Date
RU2015138677A true RU2015138677A (ru) 2018-12-25

Family

ID=43014101

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2015138677A RU2015138677A (ru) 2009-08-17 2010-08-16 Применение ингибиторов nkg2d для лечения сердечно-сосудистых и метаболических заболеваний, таких как диабет 2 типа
RU2012105528/15A RU2566264C2 (ru) 2009-08-17 2010-08-16 Применение ингибиторов nkg2d для лечения сердечно-сосудистых и метаболических заболеваний, таких как диабет 2 типа

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2012105528/15A RU2566264C2 (ru) 2009-08-17 2010-08-16 Применение ингибиторов nkg2d для лечения сердечно-сосудистых и метаболических заболеваний, таких как диабет 2 типа

Country Status (11)

Country Link
US (2) US20120148581A1 (https=)
EP (1) EP2467152B1 (https=)
JP (2) JP5838158B2 (https=)
KR (1) KR20120090931A (https=)
CN (1) CN102548573B (https=)
AU (1) AU2010284428B2 (https=)
BR (1) BR112012002353A2 (https=)
CA (1) CA2769409A1 (https=)
MX (1) MX2012001999A (https=)
RU (2) RU2015138677A (https=)
WO (1) WO2011022334A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2747785A4 (en) * 2011-08-26 2015-04-15 Univ California METHOD AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASES THROUGH NKG2D INHIBITION
EP2790696A1 (en) * 2011-12-16 2014-10-22 Atopix Therapeutics Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
JP6200437B2 (ja) 2012-03-16 2017-09-20 ユニバーシティ ヘルス ネットワーク Ｔｏｓｏ活性を調節するための方法および組成物
US20140235552A1 (en) * 2013-02-15 2014-08-21 Claresa Levetan Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agent
JP2016523264A (ja) * 2013-07-03 2016-08-08 ユニバーシティ ヘルス ネットワーク Ｔｏｓｏに対する抗体
US20200157541A1 (en) * 2018-11-19 2020-05-21 Exosome Therapeutics, Inc. Exosome loaded therapeutics for the treatment of non-alcoholic steatohepatitis, diabetes mellitus type 1 and type 2, atherosclerotic cardiovascular disease, and alpha 1 antitrypsin deficiency
US12312584B2 (en) 2018-10-02 2025-05-27 Exosome Therapeutics, Inc. cGMP exosome loaded therapeutics for treating sickle cell disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004027902D1 (de) * 2003-03-24 2010-08-12 Scripps Research Inst Dna-vakzine gegen tumorwachstum und anwendungsverfahren dafür
US7666417B2 (en) * 2003-04-22 2010-02-23 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
KR100912994B1 (ko) * 2004-04-05 2009-08-21 더 리전트 오브 더 유니버시티 오브 캘리포니아 Ｎｋｇ２ｄ의 조절
WO2008014035A2 (en) * 2006-07-25 2008-01-31 The Regents Of The University Of California Modulation of nkg2d and method for treating or preventing solid organ allograft rejection
KR101615935B1 (ko) * 2007-12-14 2016-04-28 노보 노르디스크 에이/에스 인간 ｎｋｇ2ｄ에 대한 항체 및 그것의 용도

Also Published As

Publication number Publication date
EP2467152A1 (en) 2012-06-27
AU2010284428B2 (en) 2014-09-11
JP5838158B2 (ja) 2015-12-24
RU2566264C2 (ru) 2015-10-20
AU2010284428A1 (en) 2012-02-16
EP2467152B1 (en) 2017-05-17
JP2016014030A (ja) 2016-01-28
KR20120090931A (ko) 2012-08-17
WO2011022334A1 (en) 2011-02-24
RU2012105528A (ru) 2013-09-27
CA2769409A1 (en) 2011-02-24
US20120148581A1 (en) 2012-06-14
CN102548573B (zh) 2016-03-16
US20150376281A1 (en) 2015-12-31
MX2012001999A (es) 2012-02-29
CN102548573A (zh) 2012-07-04
JP5978362B2 (ja) 2016-08-24
JP2013502420A (ja) 2013-01-24
BR112012002353A2 (pt) 2018-03-13

Similar Documents

Publication Publication Date Title
RU2015138677A (ru) Применение ингибиторов nkg2d для лечения сердечно-сосудистых и метаболических заболеваний, таких как диабет 2 типа
RU2020111236A (ru) Терапевтическое дозирование нейрегулина или его подпоследовательности для лечения или профилактики сердечной недостаточности
JP2015519050A5 (https=)
RU2012137498A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
RU2552169C3 (ru) Высокоаффинные человеческие антитела к pcsk9
WO2008050329A3 (en) Novel sirnas and methods of use thereof
WO2011146568A8 (en) Predicting response to a her inhibitor
RU2012137502A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
EA200801521A1 (ru) Лиганды, которые обладают специфичностью связывания к vegf и/или egfr, и способы их применения
EA200801842A1 (ru) Антитела против бета-амилоидного пептида
HRP20170557T2 (hr) Mikrorna spojevi i postupci za modulaciju aktivnosti mir-21
RU2015143242A (ru) Антитела против gdf8 человека
RU2012137504A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
RU2013114365A (ru) Лечение инфаркта миокарда с использованием антагонистов tgf-бета
NZ706986A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
HRP20160392T1 (hr) Cjepivo pcsk9
EA201070740A1 (ru) Способ лечения перелома кости антителами против склеростина
EA201200329A3 (ru) Ингибиторы мет для повышения эффективности лучевой терапии
RU2017104800A (ru) Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh)
JP2008508279A5 (https=)
EP3276004A3 (en) Methods for treating chronic kidney disease
WO2007101232A3 (en) Inhibition of jak2 as a treatment of pulmonary arterial hypertension
JP2013542179A5 (https=)
EA201300988A1 (ru) Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол
EA201101643A1 (ru) ВАРИАНТЫ ПРИМЕНЕНИЯ IL-1β АНТИТЕЛ И ИХ СВЯЗЫВАЮЩИХ ФРАГМЕНТОВ В СЕРДЕЧНО-СОСУДИСТОЙ СИСТЕМЕ